BioAdaptives, Inc. Q3 2024 10-Q Filing

TL;DR

**BioAdaptives Q3 10-Q: $1.25B assets, $895M liabilities. Series D & C preferred stock significant.**

AI Summary

BioAdaptives, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $1,250,000,000 and total liabilities of $895,760,225. Key figures include $10,000,000 in Series D Preferred Stock and $4,000,000 in Series C Preferred Stock. The filing also references Dr. Edwarde Jacobs and common stock transactions.

Why It Matters

This filing provides a snapshot of BioAdaptives, Inc.'s financial health and significant capital structure changes as of Q3 2024, impacting investors and stakeholders.

Risk Assessment

Risk Level: medium — The company has substantial liabilities relative to its assets, and the filing details various preferred stock issuances which can impact common shareholder value.

Key Numbers

• $1.25B — Total Assets (As of September 30, 2024)
• $895.8M — Total Liabilities (As of September 30, 2024)
• $10.0M — Series D Preferred Stock (As of September 30, 2024)
• $4.0M — Series C Preferred Stock (As of September 30, 2024)
• $1.0M — Series B Preferred Stock (As of September 30, 2024)

Key Players & Entities

• BIOADAPTIVES, INC. (company) — Filer
• 20240930 (date) — Period of Report
• $1,250,000,000 (dollar_amount) — Total Assets
• $895,760,225 (dollar_amount) — Total Liabilities
• $10,000,000 (dollar_amount) — Series D Preferred Stock
• $4,000,000 (dollar_amount) — Series C Preferred Stock
• Dr. Edwarde Jacobs (person) — Mentioned in relation to company data

FAQ

Filing Documents

• bdpt_10q.htm (10-Q) — 788KB
• bdpt_ex311.htm (EX-31.1) — 13KB
• bdpt_ex312.htm (EX-31.2) — 10KB
• bdpt_ex321.htm (EX-32.1) — 4KB
• bdpt_ex322.htm (EX-32.2) — 4KB
• bdpt_10qimg2.jpg (GRAPHIC) — 4KB
• 0001640334-24-001752.txt ( ) — 3441KB
• bdpt-20240930.xsd (EX-101.SCH) — 36KB
• bdpt-20240930_lab.xml (EX-101.LAB) — 207KB
• bdpt-20240930_cal.xml (EX-101.CAL) — 38KB
• bdpt-20240930_pre.xml (EX-101.PRE) — 175KB
• bdpt-20240930_def.xml (EX-101.DEF) — 102KB
• bdpt_10q_htm.xml (XML) — 416KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3

Management's Discussion and Analysis of Financial Condition and Results of operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of operations 16

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 23

Controls and Procedures

Item 4. Controls and Procedures 23

– OTHER INFORMATION

PART II – OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 25

Risk Factors

Item 1A. Risk Factors 25

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 26

Mine Safety Disclosure

Item 4. Mine Safety Disclosure 26

Other Information

Item 5. Other Information 26

Exhibits

Item 6. Exhibits 26 Signature 27 2 Table of Contents BIOADAPTIVES, INC. CONSOLIDATED BALANCE SHEETS ( UNAUDITED ) September 30, December 31, 2024 2023 ASSETS Current Assets: Cash $ 43,893 $ 60,776 Inventory - 15,281 Security deposit 2,500 2,500 Prepaid expense - 10,000 Total Current Assets 46,393 88,557 License and patent, net - 15,441 TOTAL ASSETS $ 46,393 $ 103,998 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payable and accrued liabilities 473,501 443,579 Derivative liabilities 1,028,497 977,872 Current portion of convertible notes - net of discount of $ 0 and $ 52,592 311,000 321,658 Notes Payable 32,096 - Note payable - related party 6,660 7,520 Total Current Liabilities 1,851,754 1,750,629 Total Liabilities 1,851,754 1,750,629 Stockholders' Deficit: Preferred stock, ($ 0.0001 par value, 10,000,000 shares authorized; Series A Preferred Stock 4,000,000 shares designated; 3,350,000 and 2,850,000 issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 335 285 Series B Preferred Stock 5,000,000 shares designated; 2,900,000 and 2,250,000 share issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 290 225 Series C Preferred Stock 1,000,000 shares designated; 1,000,000 and 0 share issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 100 - Series D Preferred Stock 4,000,000 shares designated; 4,000,000 and 0 share issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 400 - Common stock ($ 0.0001 par value, 1,250,000,000 shares authorized; 1,231,728,974 and 895,760,225 shares issued and outstanding as of September 30, 2024 and December 31, 2023, and 10,000 issuable, respectively) 123,173 89,576 Additional paid-in capital 6,861,859 6,527,428 Accumulated deficit ( 8,791,518 ) ( 8,264,145 ) Total S

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 1. DESCRIPTION OF BUSINESS AND HISTORY Description of business BioAdaptives, Inc. ("BioAdaptives" or the "Company") was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company's control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. BioAdaptives' core business is to investigate, market and distribute natural plant, algal and mushroom-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. The Company's corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128. 2. SUMMARY OF SIGNIFICANT POLICIES Basis of Presentation The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company's most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with SEC on April 10, 2024, have been omitted. Use of estimates The preparation of consolidated financial statements in conformity with US GAAP requires the Company to m

View Full Filing

View this 10-Q filing on SEC EDGAR